St. Jude doctors implement model pediatric cancer program in El Salvador: featured at American Society of Hematology meeting, December 6

December 04, 1999

Featured at American Society of Hematology Meeting, December 6

(MEMPHIS, TENN., DECEMBER 5, 1999) A model program proven to dramatically increase cure rates for pediatric cancer is being established by St. Jude Children's Research Hospital, Memphis, Tennessee. Dr. Judy Wilimas, St. Jude Director of Central American Programs in the International Outreach Department, will be a featured presenter at the American Society of Hematology Meeting, December 3-6. Wilimas' paper on the international outreach program in El Salvador was chosen from more than 5,000 abstracts as an example of innovative and outstanding work in the field of hematology/oncology. The program will serve as a model for international outreach programs around the world.

Pediatric oncology is one of the success stories of modern medicine in developed countries, with cure rates approaching 80 percent for many tumors. However, 75 percent of the world's pediatric cancer patients live in developing countries. Children living in these countries, such as El Salvador, are faced with a far less hopeful statistic - a cure rate of at best 25 percent. Recognizing these inequities, in 1993, St. Jude staff created a successful pediatric hematology/oncology partnership program in El Salvador. They brought St. Jude's leading cancer treatment to El Salvador and offered children and families new hope for cancer survival.

This new program uses modern methods to diagnose and treat all types of pediatric cancer, specifically the most common form of childhood cancer, acute lymphoblastic leukemia (ALL). More than 80 percent of the children enrolled in this new program achieved remission, and 50 to 70 percent of the children are cured.

"There is a huge unmet need in the world in terms of treating children with diseases like cancer," Wilimas said. "As rudimentary health care and nutrition needs are increasingly met, it becomes possible to address catastrophic childhood illnesses such as cancer. With programs like the one in El Salvador, it is possible to improve cure rates so dramatically - by 40 to 50 percent."

The St. Jude El Salvador program identified five major components for developing a successful program. First, the involvement of local leaders who provided support and identified funding sources for the program. Second, careful evaluation of resources and needs. Third, the training of physicians, nurses, laboratory personnel and fundraisers. Fourth, financial support for operational needs, including physician's salaries, equipment, laboratory testing, drugs and educational programs. Fifth, a standardized treatment approach, in this case for leukemia, based on a modified St. Jude protocol.

Wilimas said she thinks leaders and health care providers in developing countries are eager to develop such programs to improve the survival of children.

"When I was working with medical staff in El Salvador, I was impressed by the level of dedication I witnessed," Wilimas said. "Nurses were eager to obtain new knowledge and training, even though this meant extra work - and no extra pay - for them. Their motivation, simply, is to save the children."

"It is so fulfilling to see this type of growth and development from a world health perspective," Wilimas said.

St. Jude Children's Research Hospital in Memphis, Tennessee, was founded by the late entertainer Danny Thomas. The hospital is an internationally recognized biomedical research hospital dedicated to finding cures for catastrophic diseases of childhood. The hospital's work is supported through funds raised by the American Lebanese Syrian Associated Charities (ALSAC). All patients are treated regardless of their ability to pay. ALSAC covers all costs of treatment beyond those reimbursed by third party insurers and total costs for families who have no insurance.
For more information, contact Deidre Malone or Bert Kelly, St. Jude public relations at 901-495-3306 or Lorna Bennett, Porter Novelli, 312-856-8857

Porter Novelli

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to